Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial
· smallcaps.com.au
Amplia Therapeutics partners with Eli Lilly for a Phase 1b/2b NSCLC trial of narmafotinib plus olomorasib, targeting KRAS G12C resistance and expanding market.
Amplia Therapeutics (ASX: ATX) will partner with US drug maker Eli Lilly & Company on a Phase 1b/2b clinical trial to assess the combination of Amplia’s inves...